Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Simtuzumab - Gilead Sciences

Drug Profile

Simtuzumab - Gilead Sciences

Alternative Names: AB-0024; Anti-LOXL2 monoclonal antibody; GS-6624

Latest Information Update: 13 Jul 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Arresto Biosciences
  • Developer Gilead Sciences
  • Class Antifibrotics; Antineoplastics; Hepatoprotectants; Monoclonal antibodies
  • Mechanism of Action Chemokine CXCL12 inhibitors; Connective tissue growth factor inhibitors; LOXL2 protein inhibitors; Transforming growth factor beta1 inhibitors; Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Primary sclerosing cholangitis
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Colorectal cancer; Hepatic fibrosis; Idiopathic pulmonary fibrosis; Liver cirrhosis; Myelofibrosis; Non-alcoholic steatohepatitis; Pancreatic cancer; Primary sclerosing cholangitis

Most Recent Events

  • 19 May 2023 Pharmacodynamics data from a phase II trial in Idiopathic pulmonary fibrosis presented at the 119th International Conference of the American Thoracic Society (ATS-2023)
  • 11 Apr 2018 Pooled efficacy data from two phase IIb trials in indication) presented at the Nonalcoholic steatohepatitis and Cirrhosis presented at The International Liver Congress 2018 (ILC-2018)
  • 20 Apr 2017 Interim efficacy data from a phase IIb trial in Non-alcoholic steatohepatitis released by Gilead Sciences
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top